000			02039 a2200589 4500
005			20250514035107.0
264		0	_c20021017
008			200210s 0 0 eng d
022			_a1352-0504
024	7		_a10.1046/j.1365-2893.2002.00361.x _2doi
040			_aNLM _beng _cNLM
100	1		_aLau, G K K
245	0	0	_aThymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. _h[electronic resource]
260			_bJournal of viral hepatitis _cJul 2002
300			_a280-7 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_a2-Aminopurine _xanalogs & derivatives
650	0	4	_aAdjuvants, Immunologic _xtherapeutic use
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aCell Division
650	0	4	_aCells, Cultured
650	0	4	_aCytokines _xbiosynthesis
650	0	4	_aDNA, Viral _xblood
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFamciclovir
650	0	4	_aFemale
650	0	4	_aHepatitis B Core Antigens _ximmunology
650	0	4	_aHepatitis B Surface Antigens _ximmunology
650	0	4	_aHepatitis B e Antigens _xblood
650	0	4	_aHepatitis B virus _xgenetics
650	0	4	_aHepatitis B, Chronic _xblood
650	0	4	_aHumans
650	0	4	_aImmune Tolerance
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aT-Lymphocytes _xdrug effects
650	0	4	_aThymalfasin
650	0	4	_aThymosin _xanalogs & derivatives
650	0	4	_aTime Factors
700	1		_aNanji, A
700	1		_aHou, J
700	1		_aFong, D Y T
700	1		_aAu, W-S
700	1		_aYuen, S-T
700	1		_aLin, M
700	1		_aKung, H-F
700	1		_aLam, S-K
773	0		_tJournal of viral hepatitis _gvol. 9 _gno. 4 _gp. 280-7
856	4	0	_uhttps://doi.org/10.1046/j.1365-2893.2002.00361.x _zAvailable from publisher's website
999			_c11976285 _d11976285